UnknownNot Applicable

Research on the Role of SLC1A5 in the Development of Esophageal Cancer

China100 participantsStarted 2015-12

Plain-language summary

To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with histologically proven esophageal cancer;
✓. Age ≥18 years;
✓. All patients must sign consent forms voluntarily;

Exclusion criteria

✕. Inability to obtain histologic proof of malignancy.
✕. Age \<18 years;

What they're measuring

optical density (ODs) of each slice by immunohistochemistry assay

Timeframe: within one year (plus or minus 1 month) after surgery

Trial details

NCT IDNCT02633436

SponsorFourth Affiliated Hospital of Guangxi Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-07

Contact for this trial

Shengming Dai, Dr.

+86 13978026884 daishm@sina.com

View on ClinicalTrials.gov More Esophageal Cancer trials